{"id":"insulin-canaglifozin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Diabetic ketoacidosis"},{"rate":null,"effect":"Volume depletion"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin acts as a replacement hormone to facilitate glucose uptake and utilization in peripheral tissues. Canagliflozin, an SGLT2 inhibitor, blocks reabsorption of filtered glucose in the proximal tubule, promoting urinary glucose excretion. Together, they address hyperglycemia through distinct mechanisms: insulin-mediated glucose utilization and SGLT2-mediated renal glucose loss.","oneSentence":"This combination product delivers insulin for glycemic control while canagliflozin inhibits SGLT2 to increase urinary glucose excretion, providing complementary glucose-lowering effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:07.513Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Insulin/Canaglifozin","genericName":"Insulin/Canaglifozin","companyName":"University of Campania Luigi Vanvitelli","companyId":"university-of-campania-luigi-vanvitelli","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination product delivers insulin for glycemic control while canagliflozin inhibits SGLT2 to increase urinary glucose excretion, providing complementary glucose-lowering effects. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}